Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $14.2 million.

  • BioXcel Therapeutics' Shares Outstanding (Weighted Average) rose 43590.03% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 43590.03%. This contributed to the annual value of $2.5 million for FY2024, which is 3920.92% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Shares Outstanding (Weighted Average) of $14.2 million as of Q3 2025, which was up 43590.03% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Shares Outstanding (Weighted Average) registered a high of $29.3 million during Q3 2023, and its lowest value of $1.8 million during Q4 2023.
  • Its 4-year average for Shares Outstanding (Weighted Average) is $15.8 million, with a median of $14.2 million in 2025.
  • Per our database at Business Quant, BioXcel Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9349.99% in 2023 and then surged by 43590.03% in 2025.
  • Over the past 4 years, BioXcel Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $28.0 million in 2022, then crashed by 93.5% to $1.8 million in 2023, then skyrocketed by 39.21% to $2.5 million in 2024, then surged by 460.0% to $14.2 million in 2025.
  • Its last three reported values are $14.2 million in Q3 2025, $7.8 million for Q2 2025, and $4.8 million during Q1 2025.